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ABSTRACT
Papillary thyroid cancer (PTC) is the most prevalent endocrine neoplasia. The 
increased incidence of PTC in patients with thyroiditis and the frequent immune 
infiltrate found in PTC suggest that inflammation might be a risk factor for PTC 
development. The CXCR3-ligand system is involved in thyroid inflammation and CXCR3 
has been found upregulated in many tumors, suggesting its pro-tumorigenic role 
under the inflammatory microenvironment. CXCR3 ligands (CXCL4, CXCL9, CXCL10 
and CXCL11) trigger antagonistic responses partly due to the presence of two splice 
variants, CXCR3A and CXCR3B. Whereas CXCR3A promotes cell proliferation, CXCR3B 
induces apoptosis. However, the relation between CXCR3 variant expression with 
chronic inflammation and PTC development remains unknown. Here, we characterized 
the expression pattern of CXCR3 variants and their ligands in benign tumors and PTC. 
We found that CXCR3A and CXCL10 mRNA levels were increased in non-metastatic 
PTC when compared to non-neoplastic tissue. This increment was also observed in a 
PTC epithelial cell line (TPC-1). Although elevated protein levels of both isoforms were 
detected in benign and malignant tumors, the CXCR3A expression remained greater 
than CXCR3B and promoted proliferation in Nthy-ori-3-1 cells. In non-metastatic 
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PTC, inflammation was conditioning for the CXCR3 ligands increased availability. 
Consistently, CXCL10 was strongly induced by interferon gamma in normal and tumor 
thyrocytes.
Our results suggest that persistent inflammation upregulates CXCL10 expression 
favoring tumor development via enhanced CXCR3A-CXCL10 signaling. These findings 
may help to further understand the contribution of inflammation as a risk factor in 
PTC development and set the basis for potential therapeutic studies.
INTRODUCTION
Thyroid cancer has one of the fastest growths 
in incidence when compared to other malignant and 
endocrine neoplasia [1, 2], where papillary thyroid 
cancer (PTC) represents approximately 80% of thyroid 
malignancies [3, 4]. Based on recent data showing a 
sharp increase in its rate of incidence, PTC is predicted to 
become the fourth most common malignancy by 2030 in 
United States [5]. Usually, 20% of patients develop lymph 
node metastasis (LNM) which is associated with increased 
patient morbidity and mortality [6, 7].
A remarkable progress has been made in the 
understanding of the oncogenic mechanisms that promote 
thyroid cancer development and progression. The 
inflammatory state of premalignant and malignant lesions 
play decisive roles in tumor initiation and progression 
[8]. Specific chronic inflammatory conditions that 
increase the risk of cancer development by promoting 
the infiltration of inflammatory cells to premalignant 
lesions and the oncogene signaling that initiate cancer by 
inducing the inflammation-related genes expression are 
known mechanisms that link inflammation with cancer 
[9]. Chronic thyroiditis has been reported in 20 to 50% of 
PTC cases [10, 11] and is associated to an increased risk 
of developing PTC [12–14]. Also, the higher incidence 
of PTC in patients with chronic lymphocytic thyroiditis 
or Hashimoto autoimmune thyroiditis (HT) [15–17] has 
suggested a role of inflammation as a predisposing factor 
in the development of thyroid cancer [18–20]. Even in 
the absence of any signs of HT, remarkable peritumoral 
lymphocytic infiltrate or focal lymphocytic thyroiditis is 
frequently found in PTC [18] which is significantly higher 
and more frequent than in benign thyroid lesions [21]. As 
lymphocytic infiltrate is generally found in the peritumoral 
environment of PTC, it has been suggested that it favors 
the development of PTC [22]. Thyroid cancers arising in 
the context of HT exhibit a better prognosis than PTCs 
without chronic lymphocytic thyroiditis [23, 24]. In the 
absence of typical signs of HT, poorly differentiated and 
anaplastic thyroid carcinomas, which are associated with a 
worse prognosis, generally exhibit a reduced lymphocytic 
infiltrate compared to PTCs [11]. However, there is still 
no clear evidence whether thyroid inflammation promotes 
tumor development and/or plays a protective role against 
thyroid cancer progression.
Phenomena related with inflammation, such 
as elevated cytokine and chemokine levels, have 
been suggested to predispose to RET proto-oncogene 
rearrangements (RET/PTC), a classic oncogene that 
induced malignant transformation in thyrocytes [18]. In 
turn, RET/PTC promoted PTC oncogenesis through a 
transcriptional program that included upregulation of 
chemokines and their receptors creating an inflammatory 
environment that triggers a pro-tumorigenic response 
[18, 25–29]. Furthermore, increased levels of proteins 
from this “inflammatory program” have been detected in 
primary thyroid tumors of patients with LNM [25, 30]. 
Therefore, accumulating evidence suggests that there is 
a strong association between inflammation and increased 
risk to neoplastic transformation and progression in 
thyroid cancer [18–20, 31–33].
Inflammation is a key component of the tumor 
microenvironment and chemokines are part of the 
inflammatory network of mediators associated to neoplasia 
[34]. Frequently, chemokines and chemokine receptors are 
found in tumors and often their expression and signaling 
are deregulated [35, 36]. In fact, chemokine receptor 
signaling in malignant cells promotes tumor growth, 
invasion and metastasis [37–41]. Spread of tumor cells to 
chemokine gradients is restricted to specific patterns of 
chemokine receptors and to chemokine availability in the 
tumor microenvironment [42, 43]. Inflammatory cytokines 
produced by tumor cells and/or by tumor associated 
leukocytes may contribute to malignant progression [44]. 
Growing amount of evidence indicate that IFN-ɣ inducible 
chemokines (CXCL9, CXCL10 and CXCL11) and 
CXCR3 (their main receptor) [45, 46] play an important 
role in the initial stage of autoimmune thyroiditis [47, 48].
In thyroid tissues, secreted levels of CXCL10 are 
associated with T helper 1 (Th-1) cell infiltration which is 
commonly found in autoimmune thyroiditis and has been 
closely related to thyroid tumors [49]. Th-1 lymphocytes 
recruited to a tumor site may be responsible for enhanced 
production of IFN-γ and tumor necrosis factor-α (TNF-α) 
which in turn stimulates CXCL10 secretion from a variety 
of cells helping to maintain and potentiate cytokine 
production in the tumor microenvironment [50]. Since 
IFN-γ induces the secretion of CXCR3 ligands and 
CXCL10 in normal [51, 52] and PTC thyrocytes [53], it 
has been proposed that CXCR3 chemokines may promote 
thyroid malignant transformation and/or thyroid cancer 
progression [54–57]. In fact, the CXCR3 system plays 
a pivotal role in the malignancy process. The CXCR3 
angiostatic activity is complemented with its ability to 
potentiate the anti-tumor immunity in several tumor 
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systems [58–60]. However, upregulation of the receptor 
has been reported in many human tumors and is frequently 
associated with LNM and poor prognosis [61]. IFN-γ 
inducible chemokines have shown to promote malignancy 
by inducing cell migration of solid tumors to metastatic 
sites [62–64]. In lymph nodes, CXCL9 and CXCL10 
upregulation is induced by activated Th-1 lymphocytes 
that secretes IFN-γ [62, 65, 66]. Moreover, CXCR3 
expression levels in primary tumor were causatively 
involved in LNM [62]. These observations suggest 
that host and tumor cells can exploit IFN-γ inducible 
chemokines to promote their neoplastic transformation 
and cancer progression through CXCR3 signaling.
CXCR3 chemokines may have divergent effects on 
tumor cells in part dictated by the array of two functionally 
CXCR3 splicing variants; CXCR3A and CXCR3B [46, 
67]. While CXCR3A signaling (by CXCL10 and CXCL11) 
promotes cell viability, proliferation, angiogenesis and 
inhibits apoptosis, CXCR3B promotes an angiostatic 
effect and apoptosis [46]. The relative expression of 
CXCR3 variants is important for regulating proliferation 
and survival in several cancer cells [67–69] and correlates 
with tumor dissemination and metastasis [70–73]. In 
human renal, ovarian, prostate and breast cancer tissues, 
CXCR3A is upregulated while CXCR3B is markedly 
decreased [67, 68, 73, 74]. Although mRNA levels for 
CXCR3, CXCL10 and CXCL11 were increased in thyroid 
cells carrying mutations in the RET/PTC-RAS-BRAF axis 
[27], no studies have addressed the contribution for the 
CXCR3-ligand system in PTC development and LNM.
In this study, we determined the expression pattern 
of CXCR3 variants and their ligands in PTC and in benign 
thyroid tumors and compared them with non-malignant 
thyroid tissue. In addition, to investigate if the isoform 
expression profile is associated with cancer progression or 
inflammation, we analyzed this pattern in patients with and 
without LNM or chronic thyroiditis. Here we demonstrate, 
to our knowledge, for the first time that protein levels of 
both CXCR3 isoforms are progressively upregulated in 
benign and malignant tumors where CXCR3A expression 
remains as the predominant isoform and promotes cell 
proliferation in Nthy-ori-3-1 by CXCL10 and CXCL11 
stimulation. CXCL10 is upregulated only in PTC 
patients with thyroiditis and is significantly induced by 
IFN-γ in normal and cancer epithelial cells. Overall, our 
findings suggest a potential role of inflammation in PTC 
tumorigenesis through CXCR3A-CXCL10 enhanced 
proliferative signaling.
RESULTS
Increased CXCR3 expression in human PTC 
tissues
CXCR3 expression was analyzed by 
immunohistochemistry in 30 PTC tumors (14 non-
metastatic PTC (nMPTC) and 16 metastatic PTC 
(MPTC) and in their contralateral tissue. Histological 
features for PTC specimens and distribution of PTC 
tumors analyzed by immunohistochemistry are shown 
in Table 1. CXCR3 was mainly detected in follicular 
cells (Figure 1A, section d and inset). The quantitative 
analysis of immunoreactivity showed a 4-fold increase 
of average staining intensity for CXCR3 expression in 
PTC (409.5±179.8) vs. PTC-CLT (121.2±89.3, p<0.0001) 
(Figure 1B). CXCR3 immunoreactivity showed reduced 
risk to develop extrathyroidal extension (OR 0.09, 95% IC 
0.01–0.74) (Table 2). No associations were found between 
CXCR3 staining with the others histopathological features 
evaluated (tumor size, lymph vascular invasion, LNM and 
thyroiditis). Additionally, the percentage of positive cells 
for CXCR3 immunostaining was higher in PTC (85%) than 
in PTC-CLT (51%, p<0.0001) (Figure 1C). The frequency 
graph of CXCR3 positive cells showed that most of PTC 
Table 1: Histopatological features of PTC specimens 
analyzed by immunohistochemistry
PTC Specimens (n=34)
Sex
 Male 8 (24%)
 Female 26 (76%)
Age (years)
 < 45 18 (53%)
 ≥ 45 16 (47%)
Size (cm)
 < 2 13 (38%)
 > 2 21 (62%)
Histology (Cancer)
 PTC - UV 24 (71%)
 PTC - FV 10 (29%)
Lymphonodal Metastasis
 No 18 (53%)
 Central 5 (15%)
 Lateral 11 (32%)
Thyroiditis
 No 22 (65%)
 Yes 12 (35%)
For immunohistochemistry analysis, the distribution of 
PTC tumors was, PTC - UV (Usual variant, 24 cases), 
PTC - FV (Follicular variant, 10 cases). PTC with LNM 
(MPTC, 16 cases) and PTC patients without LNM 
(nMPTC, 18 cases). PTC specimens with thyroiditis were 
12 cases and without thyroiditis, 22 cases.
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Figure 1: Increased CXCR3 expression in human PTC tissues. (A) Representative photomicrographs from immunohistochemistry 
analysis of CXCR3 expression in PTC tumors and their matched contralateral tissues (PTC-CLT). PTC-CLT (a, c) and PTC (b, d) tissue samples 
incubated with primary antibody (c, d) or left without CXCR3 antibody (a, b) for background determination. Inset = Higher magnification of 
the area in the frame d. Scale bar = 50 μm. Magnifications in 400x. (B) Quantitative analysis of CXCR3 staining intensity in 30 PTC tumors 
and their PTC-CLT was performed as described in materials and methods. (C) Quantitative analysis of percentage of positive cells for CXCR3 
immunostaining in 30 PTC tumors. (D) Frequency graph of low, moderate and high percentage of positive cells for CXCR3 immunostaining 
in 30 PTC tumors and 30 PTC-CLT. 14 PTC specimens were non-metastatic PTC (nMPTC) and 16 metastatic PTC (MPTC) (E). Data was 
plotted as bar graphs and represent mean ± s.e.m. Statistical analysis was performed using a paired two-tailed t-test (***p<0.001).
Table 2: Association between histopathological features and CXCR3 immunoreactivity by univariate analysis
Tumor Size (≥ 2 cm) Extrathyroid 
Extension
Lymphovascular 
Invasion
Lymphonodal 
Metastasis
Thyroiditis
Immunoreactivity
 Odds Ratio 1.38 0.08 1 0.727 2.56
 95% CI 0.29 - 6.60 0.01 - 0.74 0.19 - 5.24 0.15 - 3.49 0.49 - 13.39
Significative results are showed in bold font.
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specimens presented high frequencies (% of CXCR3 
immune reactive cells between 67-100%), whereas PTC-
CLT cases were mainly distributed in moderate (34-66%) 
and low frequencies (0-33%) (Figure 1D). A representative 
image of low, moderate and high percentage of positive 
CXCR3 reactive cells is shown in Supplementary Figure 1. 
When the CXCR3 frequency of positive cells was analyzed 
between MPTC and nMPTC specimens, no differences 
were found (Figure 1E). Thyroiditis was found in 30% of 
PTC specimens and all cases with chronic inflammation 
showed a high frequency for CXCR3 reactive cells. No 
differences were found in CXCR3 staining intensity 
between cases with or without thyroiditis. Moreover, PTC-
CLT with or without thyroiditis, showed similar CXCR3 
intensity levels (Supplementary Figure 2).
CXCR3A and CXCL10 mRNA levels increase in 
non-metastatic PTC tissues
For qPCR and western blot analyses the histological 
features for benign and PTC specimens and their 
corresponding distribution is shown in Table 3. Primer 
sequences for CXCR3 variants and their ligands are 
listed in Table 4. Next we analyzed the mRNA levels for 
CXCR3A and CXCR3B in benign nodules and in their 
contralateral tissue (B-CLT) (control tissue). CXCR3A 
was slightly but not significantly increased and CXCR3B 
was reduced by 7-fold compared to B-CLT (-6.801±15.41, 
p=0.0073) (Figure 2A). Then, we investigated if changes 
in CXCR3 mRNA profile could be associated to tumor 
development by comparing the expression of CXCR3A and 
CXCR3B in nMPTC with B-CLT. Expression of CXCR3A 
was significantly increased (1.651±3.539, p=0.0091) 
whereas CXCR3B was decreased (-2.903±4.368, 
p=0.0011) (Figure 2B). This indicates that in PTC the 
expression profile of CXCR3 variants is represented by 
increased levels of the pro-tumoral CXCR3A together 
with a reduction of the anti-tumoral CXCR3B isoform. 
To determine if the profile exhibited by the CXCR3 
variants is associated to tumor metastatic progression, 
mRNA levels of CXCR3 variants were compared between 
MPTC and B-CLT (Figure 2C) and between MPTC and 
nMPTC (Figure 2D). A significant decrease of CXCR3B 
expression was observed in MPTC (-3.84±8.66, p=0.0139) 
when compared to B-CLT, while CXCR3A levels 
remained constant (Figure 2C). In contrast, when mRNA 
levels were compared using nMPTC as control tissue, a 
significant decrease of CXCR3A expression was observed 
in MPTC (-4.876±5.279, p<0.0001) while CXCR3B 
did not significantly change (Figure 2D). To investigate 
the potential role of CXCR3 ligands in the process of 
neoplastic transformation and tumor progression, the 
mRNA levels of CXCR3 ligands were assessed in benign 
and PTC tissues. We analyzed ligands expression in benign 
nodules (B), nMPTC and MPTC by comparing to B-CLT. 
In benign nodules, CXCL11 was increased by two folds 
(2.401±17.29), although without statistical significance 
whereas CXCL4 (-13.13±18.74, p=0.0121) and CXCL9 
(-4.132±6.374, p=0.0044) were decreased (Figure 2E). 
In addition, the analysis of CXCR3 ligands revealed that 
the expression of CXCL10 and CXCL11 were increased 
in nMPTC (1.883±2.950, p=0.0023; 3.307±9.782) while 
CXCL4 mRNA levels were decreased (-4.126±10.33) 
(Figure 2F). When comparing CXCR3 ligands expression 
in nMPTC with or without thyroid inflammation respect 
to B-CLT, a significant increase of all ligands only in 
nMPTC with thyroiditis (CXCL4: 3.236±3.855, p=0.469; 
CXCL9: 5.021±4.166, p=0.0039; CXCL10: 2.713±1.574, 
p=0.0039; CXCL11: 8.121±10.21, p=0.0098) was 
observed (Figure 2G). In contrast, all ligands were 
downregulated in nMPTC without thyroiditis. Comparison 
of CXCR3 ligands expression in MPTC respect to 
B-CLT showed that CXCL4, CXCL9 and CXCL10 were 
significantly reduced (Figure 2H). Similar results were 
obtained when nMPTC was used as a control tissue. All 
ligands were decreased with statistical significance in 
MPTC, with major decreases for CXCL9 (-12.86±21.07, 
p=0.0002), CXCL10 (-12.58±23.08, p=0.0015) and 
CXCL11 (-10.35±23.08, p=0.0171), all high affinity 
CXCR3A ligands [46]. Summarizing, the results indicate 
that CXCR3A is upregulated in nMPTC, while both 
CXCR3 variants and all their ligands are significantly 
decreased in MPTC. In nMPTC, the presence of thyroiditis 
conditioned the increased expression of all CXCR3 
ligands, but CXCL10 levels increased significantly when 
compared to B-CLT.
A progressive increase in protein balance of 
CXCR3A/CXCR3B from benign tumors to PTC 
tissues
Immunohistochemistry analysis revealed that 
total CXCR3 levels were increased in PTC (Figure 1), 
however, the antibody used in this analysis did not account 
changes in the CXCR3 variants profile. To compare the 
proteins levels of CXCR3A and CXCR3B in benign 
and malignant thyroid tissue, western blot analysis was 
performed by using a CXCR3 mAb (clone 1-C6) that 
recognizes CXCR3A (41 kDa) and CXCR3B (44 kDa) 
[75] as independent bands (Supplementary Figure 5). A 
representative western blot analysis is shown in Figure 
3A. In B-CLT, benign and PTC, CXCR3A bands were 
frequently stronger than CXCR3B whereas in B-CLT 
CXCR3B expression was weakly detected. In benign 
tumors, nMPTC and MPTC tissues, both CXCR3 
variants showed a significant increase when compared to 
B-CLT (CXCR3A: p=0.0050, p=0.0014 and p=0.0353; 
CXCR3B: p=0.001, p<0.0001 and p<0.0001) (Figure 
3B). To investigate the profile of CXCR3 variants in 
tumor progression, CXCR3A and CXCR3B levels were 
compared between nMPTC and MPTC. Data showed 
that both variants were significantly downregulated 
Oncotarget2450www.impactjournals.com/oncotarget
Figure 2: CXCR3A and CXCL10 mRNA levels increases in non-metastatic PTC tissues. mRNA expression levels of target 
genes were determined by qPCR in benign and PTC tumors and in their respective matched contralateral tissues. Ct values were plotted 
using the Pfaffl’s mathematical model. (A) Relative fold change (RFC) of CXCR3A and CXCR3B in 30 benign tumors (B) in 40 non-
metastatic PTC (nMPTC) and (C) in 35 metastatic PTC (MPTC) compared to 30 benign contralateral tissues (B-CLT). (D) RFC of CXCR3A 
and CXCR3B in 35 MPTC compared to 40 nMPTC. (E) RFC for CXCL4 (n=17), CXCL9, CXCL10 and CXCL11 (n=30) in benign tumors 
compared to 30 B-CLT. (F) RFC for CXCL4 (n=28), CXCL9, CXCL10 and CXCL11 (n=40) in nMPTC compared to 30 B-CLT. (G) 
RFC for CXCL4 (n=16 without thyroiditis, n=12 with thyroiditis), CXCL9, CXCL10 and CXCL11 (n=26 without thyroiditis, n=13 with 
thyroiditis) in nMPTC compared to 30 B-CLT. (H) RFC of CXCL4 (n=21), CXCL9, CXCL10 and CXCL11 (n=34) in MPTC compared 
to 30 B-CLT. (I) RFC of CXCL4 (n=28), CXCL9, CXCL10 and CXCL11 (n=35) in MPTC compared to 40 nMPTC. In all graphs, data is 
shown as mean ± s.e.m. Statistical significance for Pfaffl’s analyses was performed using the Wilcoxon test (*p<0.05, **p<0.01, ***p<0.001).
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in MPTC (CXCR3A: 1.1190±0.4086, p=0.0184; 
CXCR3B: 0.8669±0.3755, p=0.0205) (Figure 3B). In 
fact, the association of CXCR3A and CXCR3B protein 
levels with histopathological features of PTC, tested by 
UVA (univariate analysis), showed that CXCR3A and 
CXCR3B upregulation was associated with the absence 
of lymphnode metastasis in PTC (OR 0.19, 95% IC 0.05–
0.78 for both) (Table 5).
To analyze the relative fold changes of CXCR3 
variants over B-CLT, CXCR3A and CXCR3B/α-tubulin 
Figure 3: A progressive increase in protein balance (CXCR3A/CXCR3B ratio) from benign to PTC tissues. Protein levels 
of CXCR3A and CXCR3B variants in benign and PTC tumors were determined by Western blot analysis using a monoclonal antibody 
(mAb) that discriminates CXCR3A and CXCR3B monomers by size. α-tubulin was used as a loading control. (A) Representative western 
blot. (B) Densitometric analysis showing the CXCR3A or CXCR3B/α-tubulin ratio obtained from B-CLT (n=28), benign tumors (B, n=28), 
nMPTC (n=19) and MPTC (n=24). (C) Relative fold change analysis showing the CXCR3A or CXCR3B/α-tubulin ratio normalized by 
an average ratio obtained from B-CLT (n=28) in benign tumors (B, n=28), nMPTC (n=19) and MPTC (n=24). (D) nMPTC tumors were 
categorized for the presence of thyroiditis. The CXCR3A or CXCR3B/α-tubulin ratio in 19 nMPTC tumors, with (n=6) or without (n=13) 
thyroiditis were compared to 28 B-CLT. (E) The CXCR3A or CXCR3B/α-tubulin ratio in B-CLT tissues without thyroiditis (B-CLT-T, 
n=21), thyroiditis samples (n=19) (see materials and methods), B (n=28) and nMPTC (n=18). (F) CXCR3A and CXCR3B levels were 
determined as in (B) and the CXCR3A/CXCR3B ratio (protein balance) was plotted. In all graphs, data is shown as mean ± s.e.m. Ratios 
were analyzed by Mann-Whitney test (*p<0.05, **p<0.01, ***p<0.001).
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Table 3: Histopathological features of PTC specimens analyzed by qPCR and western blot
PTC specimens (n=85) Benign specimens (n=44)
Sex
 Male 19 (22%) 9 (20%)
 Female 66 (78%) 35 (80%)
Age (years)
 < 45 55 (65%) 15 (34%)
 ≥ 45 30 (35%) 29 (66%)
Size (cm)
 < 2 62 (73%) 21 (48%)
 > 2 23 (27%) 23 (52%)
Histology (Cancer)
 PTC - UV 59 (69%)
 PTC - FV 14 (16%)
 PTC - HCV 6 (7%)
 PTC - TCV 2 (2%)
 PTC - DSV 4 (5%)
Histology (Benign)
 Hyperplastic Nodules 30 (68%)
 Follicular Adenomas 14 (32%)
Multifocality
 No 66 (78%)
 Yes 19 (22%)
Extrathyroid Extension
 No 59 (69%)
 Yes 26 (31%)
Lymphovascular Invasion
 No 74 (87%)
 Yes 11 (13%)
Lymphonodal Metastasis
 No 36 (42%)
 Central 30 (35%)
 Lateral 19 (22%)
Thyroiditis
 No 59 (69%) 32 (73%)
 Yes 26 (31%) 12 (27%)
For qPCR and Western blot analysis the distribution of PTC tumors was, PTC - UV (Usual variant, 59 cases), PTC - FV 
(Follicular variant, 14 cases), PTC - HCV (Hurthle Cell variant, 6 cases), PTC - TCV (Tall Cell variant, 2 cases) and PTC-
DSV (Diffuse-Sclerosant variant, 4 cases). Benign thyroid tumors included HP (Hyperplastic nodules, 30 cases) and FA 
(Follicular adenomas, 14 cases). PTC with LNM (MPTC) were 49 cases and PTC patients without LNM (nMPTC) were 
36 cases. Benign specimens with thyroiditis were 12 cases and without thyroiditis were 32 cases. PTC specimens with 
thyroiditis were 26 cases and without thyroiditis were 59 cases.
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ratio of each patient was divided by a B-CLT average 
ratio. Although in nMPTC, CXCR3B presented a higher 
fold change in protein levels (2.71) compared to CXCR3A 
(2.04), the latter remained as the predominant expressed 
isoform (Figure 3C). We also determined whether 
significant changes in CXCR3A and CXCR3B levels 
found in PTC could be related to the presence of thyroid-
infiltrating lymphocytes. Interestingly, the increase 
in CXCR3A and CXCR3B protein levels in nMPTC 
was higher in patients without thyroiditis (CXCR3A: 
1.7680±0.7505, p=0.0002; CXCR3B: 1.3480±0.5230, 
p<0.0001) than those with thyroiditis (CXCR3A: 
1.2210±0.3714, p=0.0459; CXCR3B: 1.0460±0.5350 
p=0.0024) (Figure 3D), suggesting that most of the 
increased protein levels of CXCR3A and CXCR3B might 
come from epithelial thyroid cells rather than from the 
inflammatory infiltrate in PTC.
It has been previously reported that the IFN-
γ-inducible chemokines and their receptor CXCR3 
potentiate the initiation of HT [13]. Our results showed 
an increased level of CXCR3 ligands in nMPTC tissues 
with thyroiditis, observation that strongly supports the 
notion that inflammation plays a key role in neoplastic 
transformation and cancer development through the 
CXCR3/ligand axis. To determine if changes in the 
CXCR3 expression profile are indeed associated to thyroid 
chronic inflammation, we analyzed the protein profile of 
CXCR3A and CXCR3B in tissues with thyroiditis and 
compared them to B-CLT, benign and nMPTC tumors. In 
this case, the contralateral tissue of benign tumors without 
thyroiditis (B-CLT-T) was used as the control tissue. 
Results showed a progressive increase in protein levels 
for CXCR3A and CXCR3B. Control tissue exhibited the 
lowest amount of protein followed by thyroiditis, benign 
and nMPTC tumors, the latter presenting the highest 
protein levels (Figure 3E). A significant increase of 
CXCR3B expression was found in thyroiditis compared 
to B-CLT (0.5747±0.433, p=0.0199), while both CXCR3 
variants showed a statistical increment in nMPTC tumors 
compared to thyroiditis (CXCR3A: 1.593±0.7143, 
p=0.0171; CXCR3B: 1.240±0.5445 p=0.0004) (Figure 
3E).
The analyses of protein balance (CXCR3A/
CXCR3B ratio) in benign tumors and cancer thyroid 
tissues showed a predominant CXCR3A expression over 
the CXCR3B isoform (Figure 3F). A significant and 
progressive decrease in the protein ratio was observed 
from B-CLT to MPTC (Figure 3F) due to a greater fold 
change increase of the CXCR3B variant. A major decrease 
in the protein balance was observed when comparing 
B-CLT and benign nodules (p=0.0292), and between 
nMPTC (p=0.0005) or MPTC (p<0.0001) with B-CLT. No 
major difference in the protein ratio was found between 
nMPTC and MPTC. Thus, results suggest that changes in 
Table 4: Primers
Gene Sequence (5’ 3’) Product (pb)
CXCR3
F: GTGGACATCCTCATGGACCT
70
R: CGGAACTTGACCCCTACAAA
CXCR3A
F: TGGTCCTTGAGGTGAGTGAC
190
R: AAGAGGAGGCTGTAGAGGGC
CXCR3B
F: AAGTACGGCCCTGGAAGACT
171
R: GGCGTCATTTAGCACTTGGT
CXCL4
F: TGAAGAATGGAAGGAAAATTTGC
91
R: GCAGCTAGTAGCTAACTCTCCAAAAGT
CXCL9
F: GTTCTGATTGGAGTGCAAGGA
146
R: ATGATTTCAATTTTCTCGCAGG
CXCL10
F: TTCAAGGAGTACCTCTCTCTAG
177
R: CTGGATTCAGACATCTCTTCTC
CXCL11
F: GTGAAGGGCATGGCTATAGC
161
R: TTGTTACTTGGGTACATTATGGAGG
RNA18S
F: CGGTACAGTGAAACTGCGAAT
154
R: TCTGATAAATGCACGCATCC
ACTB
F: CTCTTCCAGCCTTCCTTCCT
116
R: AGCACTGTGTTGGCGTACAG
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Figure 4: CXCR3A is upregulated in thyroid cancer cells (TPC-1) and promotes proliferation in the Nthy-ori-3-1cell 
line. The figure shows the expression of CXCR3 variants in Nthy-ori-3-1 and TPC-1 cell lines. (A) CXCR3A and CXCR3B mRNA 
expression was determined by qPCR. Copy number (cn) ratio for CXCR3A and CXCR3B normalized by total CXCR3 receptor was 
analyzed in Nthy-ori-3-1 and TPC-1. (B, C) Western blot analyses of total CXCR3 receptor (B) and its variants (C) in Nthy-ori-3-1 
and TPC-1 cells. Detection was achieved by using a CXCR3 polyclonal antibody (Abcam) and a monoclonal antibody (R&D Systems) 
respectively. Molecular weights are indicated in arrows and α-tubulin was used as loading control. Left panel, a representative experiment 
for each western blot analysis is displayed. Right panel, quantification of total CXCR3 receptor, CXCR3A and CXCR3B in Nthy-ori-3-1 
and TPC-1 was performed by densitometric analysis. (D) CXCR3A/CXCR3B ratio in Nthy-ori-3-1 and TPC-1 cells. The results are shown 
as CXCR3, CXCR3A or CXCR3B/α-tubulin ratio. (E) Relative cell proliferation rate for cells transfected with empty vector (pTopo), 
CXCR3A or CXCR3B. (F) Relative cell proliferation rate for cells transfected with empty vector, CXCR3A or CXCR3B stimulated with 
CXCL10 or CXCL11. All experiments were performed in triplicate and in 3 independent experiments. In all graphs, data is shown as mean 
± s.e.m and Mann-Whitney test was performed (*p<0.05, **p<0.01, ***p<0.001).
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Figure 5: Increased CXCL10 levels in thyroid cell lines and in PTC tissues. (A) Nthy-ori-3-1 and TPC-1 cells were incubated 
with or without IFN-ɣ for 24 h. in serum-free media and CXCL10 and CXCL11 levels in the supernatants were determined by ELISA. 
Secreted levels of CXCL10 and CXCL11 in basal and IFN-ɣ treated cells were quantified and plotted as bar graphs. Results are from 
three independent experiments performed in triplicate. Secretion levels are displayed as pg/mL for CXCL10 (left panel) and for CXCL11 
(right panel). (B) Histological analysis of CXCL10 expression in PTC and their PTC-CLT. Representative photomicrographs from 
immunohistochemistry experiments for CXCL10 detection in 17 PTC and their contralateral tissues (PTC-CLT). PTC-CLT (a, c) and PTC 
(b, d) tissue samples incubated with CXCL10 antibody (c, d) or left without primary antibody (a, b) for background determination. Inset = 
Higher magnification of the area in the frame. Scale bar = 50 μm. Magnifications in 400x. (C) Quantitative analysis of CXCL10 staining 
intensity in 17 PTC tumors was performed as described in materials and methods. (D) Quantitative analysis of percentage of positive cells 
for CXCL10 immunostaining in 17 PTC tumors. (E) Frequency graph of the categories of the percentage of positive cells for CXCL10 
immunostaining in 17 PTC tumors and 17 PTC-CLT. (F) Frequency graph of low, moderate or high percentage of positive cells for 
CXCL10 immunostaining in 10 non-metastatic PTC (nMPTC), 17 metastatic PTC (MPTC) and their contralateral tissue. Average staining 
intensity values and percentage of positive cells were normalized by corresponding total cell number in each slide and plotted as bar graphs. 
In all graphs, data is shown as mean ± s.e.m. Statistical analysis for chemokine secretion levels was performed using Mann-Whitney test 
and for CXCL10 immunohistochemistry was performed using a two-tailed paired t-test (*p<0.05, **p<0.01, ***p<0.001).
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the ratio of the CXCR3 variants is associated to neoplastic 
transformation and tumor growth rather than tumor 
metastasis.
CXCR3A is upregulated in papillary thyroid 
cancer epithelial cell line (TPC-1) and promotes 
proliferation in Nthy-ori-3-1 cells
Our results showed a major shift in CXCR3B 
expression than in CXCR3A. In order to clarify these 
seemingly contradictory findings and to better understand 
the CXCR3 variants profile in epithelial cells within PTC 
tissues, we analyzed their mRNA levels in Nthy-ori-3-1 
and TPC-1 cell lines. CXCR3A copy number ratio in TPC-
1 was increased by three-fold (0.158±0.089) compared 
to Nthy-ori-3-1 (0.048±0.0007), while CXCR3B 
levels were similar in both cell lines (0.0804±0.006 vs. 
0.0569±0.0229) (Figure 4A). Compared to Nthy-ori-3-1, 
protein levels of total CXCR3 were significantly increased 
in TPC-1 (p=0.0162) (Figure 4B), but in both cell lines, 
CXCR3A was the most abundant variant (Figure 4C, left 
panel). Furthermore, higher CXCR3A levels were detected 
in TPC-1 (2.091±0.269, p=0.0303) when compared to 
Nthy-ori-3-1 (1.312±0.478) (Figure 4C, right panel), 
while the opposite was observed for CXCR3B levels 
which were subtly reduced in TPC-1 (0.374±0.096 vs. 
0.724±0.359). Moreover, CXCR3B protein levels were 
significant lower than CXCR3A in Nthy-ori-3-1 and 
TPC-1 (p=0.0293 and p=0.0079 respectively) indicating 
that this cellular system recapitulates the CXCR3 profile 
progression found in control tissue and tumors (Figure 
4C, right panel). Changes in the CXCR3A and CXCR3B 
profile in Nthy-ori-3-1 and TPC-1 cells, represented by 
CXCR3A/CXCR3B ratio (also defined as CXCR3A/
CXCR3B balance) are shown in Figure 4D. CXCR3A/
CXCR3B ratio in TPC-1 was increased by two folds 
(5.547±1.575) compared to Nthy-ori 3-1 (2.490±1.570) 
(Figure 4D). Since CXCR3A was upregulated in TPC-1 
cells whereas CXCR3B expression was subtly diminished, 
but considering that CXCR3B showed higher fold change 
in protein levels than CXCR3A in nMPTC specimens, 
Nthy-ori 3-1 cells were transfected with empty vector, 
CXCR3A or CXCR3B. A significant increase in the 
relative cell proliferation rate was evidenced in CXCR3A-
overexpressing cells (1.32±0.28, p=0.0313) when 
compared to the control (Figure 4E). In contrast, CXCR3B 
overexpression induced a significant decreased in cell 
growth (0.65±0.36, p=0.0391) (Figure 4E). When cells 
were stimulated with CXCL10 or CXCL11, a statistical 
and significant increase in the cell proliferation rate was 
observed in CXCR3A overexpressing cells (p=0.0036 and 
p=0.0014, respectively) while CXCR3B transfected cells 
stimulated with CXCL10 showed a significant decreased 
in cell division (p=0.0419) (Figure 4F).
Table 6: Association between histopathological features and CXCL10 immunoreactivity by univariate analysis
Tumor Size 
(≥ 2 cm)
Extrathyroid 
Extension
Lymphovascular 
Invasion
Lymphonodal 
Metastasis
Thyroiditis
Immunoreactivity
 Odds Ratio 0.88 1.2 2.86 1.67 2.4
 95% CI 0.11 - 7.11 0.16 - 8.80 0.24 - 33.90 0.21 - 13.22 0.30 - 19.04
Significative results are showed in bold font.
Table 5: Association between histopathological features of PTC and CXCR3A or CXCR3B protein expression
Tumor Size (≥ 
2 cm)
Extrathyroid 
Extension
Lymphovascular 
Invasion
Lymphonodal 
Metastasis
Thyroiditis
CXCR3A 
Expression
 Odds Ratio 0.40 0.40 1.76 0.19 0.80
 95% CI 0.07 - 2.19 0.09 - 1.76 0.39 - 7.99 0.05 - 0.78 0.20 - 3.27
CXCR3B 
Expression
 Odds Ratio 0.40 1.11 0.96 0.19 0.46
 95% CI 0.07 - 2.19 0.29 - 4.31 0.20 - 4.57 0.05 - 0.78 0.10 - 2.07
Significative results are showed in bold font.
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CXCL11 is the predominant secreted ligand 
in thyroid epithelia but only CXCL10 is 
significantly induced by IFN-ɣ in PTC cell line
Next we sought to evaluate whether IFN-ɣ could 
promote a differential response in secreted levels of 
CXCR3 ligands in Nthy-ori-3-1 and TPC-1 cells. Under 
serum free media conditions, we found that CXCL10 
levels in Nthy-ori-3-1 and TPC-1 cells (8.276±19.94 
and 5.642±15.64 pg/ml, respectively) were lower than 
that of CXCL11 (47.08±3.585 and 46.72±2.799 pg/ml 
respectively) (Figure 5A). No statistical differences were 
Figure 6: Schematic modeling of the CXCR3 variant expression profile that is associated to thyroid benign neoplasia 
and PTC. A progressive increase in protein balance for CXCR3A (red) and CXCR3B (blue) from control tissue to benign and malignant 
(PTC) tumors is shown, with consistent predominance of CXCR3A. The increase of CXCR3A and CXCR3B in benign tumor suggests 
a neoplastic transformation role. Higher levels of CXCR3A in nMPTC suggest a role in malignant transformation or tumor growth. The 
decrease of CXCR3A and CXCR3B in MPTC compared to nMPTC suggests that CXCR3A may not be associated to thyroid tumor 
dissemination but with tumor growth. Inflammation was conditioning for CXCR3 ligand increased availability in PTC. CXCR3A and 
CXCL10 are highly expressed in nMPTC consistent with a condition that may favor neoplastic transformation and tumor growth.
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found for these ligands between both cells lines in starving 
media. In contrast, CXCL10 was robustly induced by 
IFN-ɣ and this increase was significantly higher in TPC-1 
compared to Nthy-ori-3-1 (189.8±39.47 pg/ml, p=0.0286 
vs. 129.6±12.41 pg/ml, p=0.0357). Therefore, results 
suggest that CXCL10 expression is highly induced by 
an inflammatory stimulus, such as IFN-ɣ, in normal and 
cancer thyroid epithelial cells.
CXCL10 protein levels are upregulated in PTC
To determine whether CXCL10 expression 
partially originates from epithelial cells in PTC tumors, 
immunohistochemistry assays were performed. A major 
increase in CXCL10 immunoreactivity was detected in 
PTC epithelial cells compared to PTC-CLT (Figure 5B, 
section c and d). A higher magnification image of section 
d is shown in Figure 5B. Quantitative analysis showed 
a 16-fold increase in cell intensity per cell for CXCL10 
expression in PTC (82.24±52.54 vs. 5.08±3.77, p<0.0001) 
(Figure 5C). No association was found between CXCL10 
staining and other histopathological features (Table 6). 
The percentage of cells expressing CXCL10 as determined 
by immunostaining was higher in PTC (56.46%) than in 
PTC-CLT (6.74%, p<0.0001) (Figure 5D). The frequency 
graph of CXCL10 positive cells showed that most of PTC 
specimens presented moderate or high frequencies (% of 
CXCL10 immune reactive cells between 34-66% and 67-
100%, respectively), whereas PTC-CLT cases were only 
distributed in low frequencies (% of CXCL10 immune 
reactive cells lower than 34%) (Figure 5E). When the 
CXCL10 frequency of positive cells was analyzed between 
MPTC and nMPTC specimens, cases with moderate 
frequency were very similar in both groups. In contrast, 
specimens with higher frequency of CXCL10 were more 
abundant in nMPTC than in MPTC (Figure 5F). CXCL10 
expression was found in 100% of PTC specimens and all 
of them showed high intensity (data not shown).
DISCUSSION
It has been suggested that inflammation promotes 
an increased risk to neoplastic malignant transformation in 
thyroid tissues [18] and may be involved in thyroid cancer 
progression [20]. IFN-γ-mediated CXCL10 secretion is 
associated to thyroiditis and is closely related to thyroid 
tumors [49]. However, the role of CXCR3 spliced variants 
and their relation with thyroid cancer and inflammation 
has not been addressed. We report a progressive increase 
in protein balance of CXCR3 variants when comparing 
control tissue to benign tumors and malignant thyroid 
neoplasia where CXCR3A was always the predominant 
isoform. We also report that inflammation was 
conditioning for CXCR3 ligand increased availability in 
PTC. Finally, we show that CXCR3A and CXCL10 are 
highly expressed in non-metastatic PTC and in the PTC 
epithelial cell line TPC-1, consistent with a condition that 
may favor neoplastic transformation and tumor growth.
Our initial data showed increased protein levels 
of CXCR3 and CXCL10 in PTC. CXCR3 and CXCL10 
immunoreactivity was mainly localized in epithelial 
cells within the tumor, but some minor staining was also 
observed in the inflammatory infiltrate. Thus, we cannot 
ignore a CXCR3A contribution from immune cells to the 
PTC-CXCR3A profile. In fact, a higher proportion of 
the CXCR3+/CCR5+ thyroid-infiltrating lymphocytes 
gained by fine needle aspiration biopsy has been recently 
reported in malignant nodules as compared to benign 
nodules [76] confirming some CXCR3 expression due to 
an inflammatory reaction surrounding thyroid carcinoma, 
as previously described [77]. However, our results suggest 
that the increase of CXCR3 expression in PTC is mainly 
due to an increased receptor expression in epithelial cells 
and not an exclusive contribution from the inflammatory 
infiltrate or stroma. Most of our PTC specimens with 
high CXCR3 staining were cases without thyroiditis 
and no major differences in CXCR3 immunoreactivity 
were found between PTC with or without thyroiditis. In 
addition, CXCR3A and CXCR3B protein levels in nMPTC 
were higher in patients without thyroiditis supporting that 
increased expression of CXCR3 is predominantly from 
epithelial cancer cells. In fact, we found increased protein 
levels for total receptor in TPC-1 when compared to Nthy-
ori-3-1 cells. In ovarian cancer, the protumoral variant was 
observed in the inflammatory infiltrate, but was mainly 
detected in cancer cells [74]. Taken together, these results 
suggested that the increment of CXCR3 in PTC might be 
mainly epithelial with a minor contribution from Th-1 
lymphocytes or stromal cells. Our findings prompted us 
to analyze the expression profile of CXCR3 in a papillary 
thyroid cancer cell line (TPC-1) as well as in benign and 
malignant thyroid neoplasms to determine if expression 
profiles are associated to thyroid malignant phenotypes.
Our results showed that in control tissue, if there 
is an imbalance of CXCR3 (favoring CXCR3A over 
CXCR3B levels), which gradually decreased as tissues 
becomes neoplastic (benign) and then malignant (nMPTC 
and MPTC). The increase of CXCR3A and CXCR3B 
protein levels between control and benign tumor tissue 
suggests a neoplastic transformation role for the CXCR3 
variants profile. The balance of protein levels of CXCR3A 
and CXCR3B found in nMPTC suggest that similar levels 
for CXCR3 variant might have a role during malignant 
transformation or tumor growth. In benign tumors and 
PTC, proteins levels for CXCR3A and CXCR3B were 
significantly increased when compared to B-CLT, but 
CXCR3A was the most expressed variant with highest 
levels in nMPTC. Furthermore, since (i) CXCR3 staining 
was mainly observed in epithelial cells within the tumor, 
(ii) the protein levels for CXCR3A were significantly 
higher in TPC-1 than in Nthy-ori-3-1 and (iii) CXCR3B 
protein levels in TPC-1 were significantly lower than 
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CXCR3A and (iv) CXCR3B levels in TPC-1 were lower 
than Nthy-ori-3-1), we propose that increased CXCR3 
levels found in PTC by immunohistochemistry analysis 
correspond to the CXCR3A variant mainly expressed in 
PTC epithelial cells with a minor CXCR3A expression 
from inflammatory cells [74, 78, 79].
Despite that CXCR3A was predominant in PTC 
we detected an unexpected increase of CXCR3B. In 
TPC-1, CXCR3B protein levels were not increased when 
compared to Nthy-ori-3-1 cells. These results support that 
CXCR3B increment found in benign tumors or PTC may 
originate from other cell types within the tumor rather 
than epithelial cells. CXCR3B is primarily expressed in 
endothelial cells [46], in fibroblasts and T-lymphocytes but 
it has been found in several endocrine malignant neoplasia 
[80]. In epithelial breast cancer cells, decreased mRNA 
levels for CXCR3B were induced by upregulation of 
CXCL10 [67]. Consistently, we found increased CXCL10 
at mRNA and protein levels in PTC tissues while CXCR3B 
mRNA levels were significantly downregulated. In fact, 
previous reports have shown that a significant proportion 
of freshly isolated PBMC (peripheral blood mononuclear 
cells) expressed CXCR3 at the plasma membrane while 
transcripts remained undetectable [81, 82]. Unexpectedly, 
CXCR3B proteins were increased in all tissues when 
compared to B-CLT. This may be due to a reduced receptor 
destination to proteasomes or lysosomes. Taken together, 
these results suggest a mechanism for CXCR3B mRNA 
downregulation induced by CXCL10 in PTC thyrocytes, 
reinforcing that CXCR3B protein increment found in 
PTC may not mainly come from tumoral epithelial cells. 
In ovarian and renal cancer, CXCR3B was preferentially 
detected in endothelial cells [46, 74], supporting the 
notion that CXCR3B activation may inhibit the PTC 
tumor associated angiogenesis. Other source for increased 
CXCR3B in PTC could be thyroid cancer stem cell-like 
populations, since CXCR3B has been found upregulated 
in this cells from breast cancer [70]. CXCR3B expression 
is frequently downregulated in several cancer types [67, 
73, 74, 83], consistently with a reduced anti-proliferative 
and limited angiostatic activity [46]. Over-expression 
of CXCR3B in cancer cells significantly inhibited cell 
proliferation and promoted apoptosis [45, 74, 84] and in 
renal [57, 85] and gastric cancer [86] it was associated 
with tumor necrosis extension and immune-angiostatic 
activity respectively, demonstrating an anti-tumoral role 
for CXCR3B upregulation.
Changes in CXCR3 profile expression may be related 
to initial stages of cancer development or its progression to 
metastatic disease. CXCR3A has been associated to tumor 
progression in prostate, ovarian, breast and renal cancer [73, 
74, 83]. When compared to nMPTC, a significant decrease 
of CXCR3A and CXCR3B was observed in MPTC but 
CXCR3A continued being the predominant variant. These 
results suggest that CXCR3A expression may not be 
associated to tumor thyroid dissemination. However, it has 
been reported that cells from metastatic primary tumors 
that have undergone epithelial–mesenchymal transition 
(EMT) display a reduced proliferation rate that is linked to 
dissemination and survival of metastatic cells [87] which 
would be consistent with a reduced CXCR3A expression. 
Further studies are necessary to understand how a weakened 
CXCR3A expression in MPTC could favor cell migration 
and tumor invasion.
Opposite effects for CXCR3 ligands depend on the 
array of spliced-variants and their localization (stroma 
and/or tumor cells) [80]. In nMPTC, CXCL10 and 
CXCL11 upregulation was associated to an increased 
CXCR3A expression, supporting a potential role 
for CXCR3A signaling during malignant neoplastic 
transformation. In fact, CXCR3A overexpressing cells 
promoted cell proliferation. Moreover, CXCL10 and 
CXCL11 induced significant increase in cell growth 
compared to cells transfected with empty vector. 
CXCL9, CXCL10 and CXCL11 has shown to induce 
cell proliferation on HMC, which selectively express 
CXCR3A [88, 89]. Likewise, CXCR3A overexpression 
in HEK293 cells promoted proliferation in basal and 
CXCL10 treated cells and PTX strongly reduced the 
proliferation in both conditions [46].
All CXCR3 chemokines were significantly reduced 
in MPTC when compared to nMPTC. The declining 
expression of CXCR3A and CXCR3B together with the 
low levels of CXCR3 ligands detected in MPTC, suggest 
that in cancer thyrocytes, CXCR3 signaling may not be 
involved in tumor dissemination and LNM.
Chronic inflammation in the tumor microenvironment 
plays a crucial role in tumorigenesis. Inflammatory 
cytokines and chemokines in tumor microenvironments 
attract immunosuppressive cells, and enhance EMT, tumor 
angiogenesis and cancer-stem cell formation. TNF-α is a 
master switch from chronic inflammation to cancer [90, 91]. 
Recent data has shown that TNF-α significantly increased the 
expression of CXCR2 and CXCR3 and their related ligands 
in renal cancer cells enhancing the migration, invasion and 
EMT [92]. Considering that in thyroid tissues, recruited Th-1 
lymphocytes are responsible for enhanced IFN-γ and TNF-α 
production, which in turn stimulates CXCL10 secretion in 
thyroid cells perpetuating the autoimmune process [93], 
thus TNF-α stimulation of thyrocytes would clarify whether 
inflammatory microenvironment upregulates CXCR3 
expression promoting thyroid tumorigenesis. Interestingly, 
CXCR3 ligands were statistically increased only in nMPTC 
patients with thyroiditis, indicating that the inflammation 
microenvironment is a prerequisite for increased CXCR3 
ligand availability. In fact, CXCL10 was significantly 
induced by IFN-γ in Nthy-ori-3-1 and TPC-1, as has been 
previously reported in normal and PTC primary thyrocytes 
[53]. Inflammation promoted a switch on the CXCR3 ligand 
profile in normal and cancer epithelial cells, where CXCL10 
became the predominant chemokine. Main cellular sources of 
CXCL10 in PTC tissues are Th-1 lymphocytes and mast cell 
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infiltrate [94, 95], the later which has been associated with a 
pro-tumorigenic role in PTC [95, 96].
The role of chemokines and their receptors in 
malignant transformation in the tumor microenvironment 
is still debatable. Chronic inflammation causes DNA 
damage in proliferating cells [32, 97, 98] leading to 
neoplastic transformation [32]. CXCL10 is member of 
the interferon-related DNA damage signature, linking 
CXCL10 expression with pro-tumorigenic functions. 
Inflammation may promote CXCR3 upregulation in 
PTC by inducing its promoter demethylation [99] 
or by demethylation of intron CpG sites resulting in 
increased CXCR3A levels in cancer cells [61, 100]. In 
damaged thyroid tissue with cytokines surrounding the 
premalignant lesion, early recruitment and activation of 
Th-1 leukocytes and mast cells, may lead to constitutive 
secretion of CXCL10 that in turn promotes, by paracrine 
or autocrine manner, thyrocytes (and other cells) 
survival through CXCR3A signaling. We propose 
that persistent inflammation and sustained CXCL10 
secretion, may upregulate CXCR3A in epithelial 
cells (Figure 6) promoting the malignant neoplastic 
transformation through constitutive CXCR3A-CXCL10 
signaling. Then, in malignant tissue, tumor growth and 
cell survival may be supported by CXCR3A-CXCL10 
axis, contributing to thyroid cancer progression but 
not to tumor dissemination. The function of increased 
CXCR3B expression could be related to a decreased 
tumor associated angiogenesis and to tumor dependent 
immunity. Further studies are pending to understand 
the mechanism underlying the increased CXCR3A and 
CXCR3B expression within PTC tissues and their role 
in cancer development and progression.
In conclusion, to our knowledge, this is the first 
report showing a switch in the CXCR3A/CXCR3B 
balance in PTC and its association with inflammation and 
thyroid cancer progression. The current study shows that 
CXCR3A and CXCL10 are highly expressed in PTC and 
in a PTC derived epithelial cell line (TPC-1), consistent 
with a condition that may favor tumor development and 
progression. In addition, CXCL10 is strongly induced 
by IFN-ɣ in CXCR3A over-expressing cells (TPC-1) 
suggesting that CXCR3A-CXCL10 enhanced signaling 
might induce tumor progression promoting signals in 
PTC.
MATERIALS AND METHODS
Patients and tissue samples
Surgical tissue specimens included malignant (PTC, 
with or without LNM (metastatic PTC, (MPTC) and non-
metastatic (nMPTC) respectively)) and benign (B) thyroid 
tumors. Fresh benign and PTC tumors and their respective 
contralateral tissues (B-CLT and PTC-CLT) were 
obtained from patients undergoing total thyroidectomy. 
Patients signed an informed consent approved by the 
ethics committee of the Pontificia Universidad Católica 
de Chile according to the principles expressed in the 
declaration of Helsinki. Tissue samples were divided and 
placed in 4% paraformaldehyde or protein lysis solution, 
or preserved in a RNA stabilization solution (Ambion, 
Austin TX). Inclusion criteria were patients at least 18 
years old and with a confirmed benign or malignant 
diagnosis by histopathological examination (biopsy 
report). Exclusion criteria were patients with follicular, 
medullary and anaplastic thyroid cancer. Thyroid biopsy 
chart showing benign and PTC cases distribution for 
IHQ, qPCR and WB analysis is shown in Supplementary 
Figure 3. Tissue characterization is described as follows; 
B-CLT: contralateral tissue of benign tumors considered 
as non-neoplastic and non-malignant tissue; PTC-
CLT: contralateral tissue of PTC tumors; nMPTC-CLT: 
contralateral tissue of non-metastatic PTC; MPTC-CLT: 
contralateral tissue from metastatic PTC. All contralateral 
tissues from PTC tumors were considered as non-
neoplastic and non-malignant tissue; B: benign thyroid 
tumor considered as neoplastic and non-malignant tissue; 
PTC: cancer tissue considered as neoplastic and malignant 
tissue.
PTC tumors included PTC - UV (Usual variant), 
PTC - FV (Follicular variant), PTC - HCV (Hurthle Cell 
variant), PTC - TCV (Tall Cell variant), and PTC-DSV 
(Diffuse-Sclerosant variant). Benign thyroid tumors 
included HP (Hyperplastic nodules) and FA (Follicular 
adenomas). As thyroiditis samples, the contralateral 
thyroid tissue of 7 cases of benign tumors and the 
contralateral thyroid tissues of 11 cases of PTC tumors, 
which presented severe or moderate thyroiditis in the 
biopsy report were considered (Supplementary Figure 
3). To establish our gold standard control tissue, we 
compared the mRNA levels of CXCR3A and CXCR3B 
between B-CLT and PTC-CLT tissues. Further, sub 
analysis comparing the expression for CXCR3 variants 
was performed between nMPTC-CLT and MPTC-
CLT. Expression of CXCR3A was significantly 
increased in nMPTC-CLT when compared to B-CLT, 
whereas CXCR3B levels were only slightly increased 
(Supplementary Figure 4), indicating that PTC-CLT 
may not represent a qualified control. Therefore, we 
considered B-CLT as the gold standard for non-malignant 
tissue (control) in the mRNA and protein profiles 
analyses.
Cell cultures
Nthy-ori-3-1, a normal human thyroid follicular 
epithelial immortalized cell line [101] was purchased 
from ECACC (Wiltshire, UK). TPC-1, a human PTC 
cell line derived from a PTC that expresses the RET/
PTC-1 oncogene [102], was kindly provided by Dr. J. 
A. Fagin (Memorial Sloan Kettering Cancer Center, 
Oncotarget2461www.impactjournals.com/oncotarget
New York, NY). Cells were grown in a humidified 
atmosphere containing 5% CO2 at 37°C in RPMI 1640, 
10% fetal bovine serum, penicillin-streptomycin (100 U/
ml) (Invitrogen-GIBCO, MD, USA). Nthy-ori-3-1 culture 
media was supplemented with L-glutamine 2 mM. Cell 
lines were authenticated and routinely tested for bacterial 
and Mycoplasma contamination.
Real-time PCR (qPCR) reaction and qPCR 
analyses
Expression of CXCR3 variants and ligands was 
analyzed by real time RT-PCR (qPCR) using Brilliant II 
SYBR® Green QPCR Master Mix (Stratagene) following 
the manufacturer instructions. All reactions were 
performed in triplicate using 10 ηg of cDNA. ACTB and 
RNA18S were used as control genes. Primer sequences 
for CXCR3 variants and their ligands were designed using 
the NCBI’s Primer BLAST (http://www.ncbi.nlm.nih.gov/
tools/primer-blast) and are listed in Table 4. Ct values 
were analyzed by Pfaffl’s relative quantification model 
[103] presented as relative fold changes of mRNA amount 
in target tissue respect to reference tissue (Supplementary 
Materials).
Immunohistochemistry
CXCR3 and CXCL10 protein levels in tissue 
samples were analyzed in formalin-fixed, paraffin-
embedded samples obtained from PTC tumors and their 
contralateral tissue (PTC-CLT). Clinical information 
of PTC specimens analyzed by immunohistochemistry 
is summarized in Table 1. Primary mouse monoclonal 
(mAb) anti-human CXCR3 antibody (antibody that not 
account to CXCR3 variant profile due an almost complete 
overlap between variants aminoacid sequences) [104] 
(Abcam, ab64714) and polyclonal (pAb) anti-human 
CXCL10 antibody [67] (R&D Systems, AF-266-NA) 
were used. Further details of the procedure are described 
in Supplementary Materials.
The immunoreactivity intensity values were 
determined using the Image-Pro Plus program version 
6.0 (Media Cybernetic Inc.) and the staining intensity of 
CXCR3 and CXCL10 in tumor tissue was normalized by 
total number of nuclei counted in each microphotograph 
and scored. To quantify immunoreactivity, 3 
representative digital microphotographs were taken from 
sections of tumor and matched non-neoplastic tissue. The 
average normalized values were plotted and referred as 
intensity of CXCR3 or CXCL10 per cell. Frequency 
graphs for CXCR3 and CXCL10 were obtained by 
counting the total immunoreactive positive cells in at 
least 3 fields of each slide. Percentage of positive cells 
was obtained by dividing the number of stained cells 
by total cell number in each field. The percentage of 
positive cells of CXCR3 or CXCL10 in tumor tissue 
or in the PTC-CLT was scored based on the following 
criteria: low: (0-33% of positive cells), moderate (34-
66% of positive cells) and high (67-100%). To assess the 
best cutoff value for the Odds Ratio analysis, a receiver 
operating characteristic (ROC) curve was constructed 
and analyzed (data not shown). Optimal sensitivity to 
specificity ratios were observed using the cutoff values 
of 90% of positive cells for CXCR3 and 58% of positive 
cells for CXCL10 and the immunoreactivity values of 
493 for CXCR3 and 58.8 for CXCL10.
Western blot
Western blot assays were performed for CXCR3 
and their splicing variants expression analysis in benign, 
PTC tissues and thyroid cell lines. Primary mouse mAb 
for total CXCR3 [104] (Abcam, ab64714), mouse pAb 
for CXCR3 variants [74] (R&D Systems, MAB160), and 
mouse mAb for α-tubulin [105] (SIGMA, T9026) were 
used (Supplementary Materials).
Quantitative detection of chemokines
Cells plated in 6 cm dishes were grown to 70% 
confluence. After 24 hours, cells were washed, cultured 
in serum-deprived media and treated with IFN-ɣ (10000 
U/mL) for 24 hours. Control cells were maintained in 
serum-deprived media. Supernatants were harvested and 
cleared by centrifugation at 800 g at 4°C. Chemokine 
concentration was determined in triplicates by quantitative 
immunoassay ELISA kit (QuantiKine ELISA kit; R&D 
Systems) following the manufacturer’s instructions.
Plasmids
Plasmids containing the complete open reading 
frame of CXCR3A or CXCR3B genes were obtained by 
isolating the human sequences from benign patients by 
RT-PCR reaction. PCR fragments were then cloned into 
pcDNA 3.1/V5-His © TOPO ® TA (ptopo, Invitrogene)
(USA). Variants sequences were under the control of 
CMV and T7 polymerase and alternatively fused to the 
V5 epitope, adding 45 extra aminoacids. pmCherry-V5 
plasmid was a gift from Dr. R. Fuentealba (Universidad 
Autonoma, Chile).
Transfection
Nthy-ori 3-1 cells (2×106 cells/plate) were 
transfected with 15 μg of plasmid DNA into 100 mm 
plates with lipofectamine 3000 reagent (Invitrogen Inc., 
USA), and cultured at 37°C in an atmosphere of 5% CO2 
for 48 h. Hela cells (1.5×105 cells/plate) were transfected 
with 1 μg of plasmid DNA into 30 mm plates with Fugene 
6 reagent (Promega, USA), and cultured at 37°C in an 
atmosphere of 5% CO2 for 24 h.
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MTT assays
Cell proliferation was measured by MTT cell 
proliferation assay (Trevigen, Gaithersburg, USA). 
Following transfection cells were plated (3×103 cells/well) 
in 96-well plates with no phenol red RPMI medium mixed 
with 10% fetal bovine serum and then cultured at 37°C for 
24 h. Then CXCL10 and CXCL11 were added at 100 ng/
mL and the cells were cultured for 48 h and 10 μl of MTT 
reagent was added to each well. When purple crystals of 
formazan became visible under the microscope, 100 μl of 
detergent reagent was added, and the cells were incubated 
for 2 h. Absorbance of cells in each well was observed 
at 570 nm under an absorption spectrophotometer 
(Autobio Labtec, China) and corrected against blanks 
(culture medium). Cells transfected with empty vector 
(pTopo) were considered as control. All experiments were 
conducted independently for 3 times. The reading at 570 
nm is directly proportional to cell proliferation (number 
of viable cells).
In vitro transcription
The vectors were digested with PmeI (#ER1341, 
ThermoFisher Scientific) and the RNAs were synthesized 
in a 50 μl in vitro transcription reaction for 2 h at 37°C 
using T7 RNA polymerase (#EP0111, Thermo Scientific, 
ThermoFisher Scientific), 5 mM rNTPs, 1X Ribomax 
transcription buffer (80 mM Hepes-KOH pH 7.5, 24 
mM MgCl2, 2 mM spermidine, 40 mM DTT) and 20 U 
of RNAsin (#E00382, Thermo Scientific, ThermoFisher 
Scientific). Upon synthesis, RNA was treated with 1 U 
of RQ1 DNase (#M610A, Promega) for 30 min at 37°C. 
RNA was precipitated for 2 h at -20°C with 2.5 M LiCl, 
centrifuged at 16,000 g for 30 min at 4°C, washed with 
70% ethanol and resuspended in 25 μl of nuclease-
free water. RNA concentrations were determined 
spectrophotometrically (NanoDrop Technology, 
Wilmington, DE), and RNA integrity was monitored by 
electrophoresis on agarose gels.
In vitro translation
In vitro translation reactions were carried out in 
nuclease-treated rabbit reticulocyte lysate (RRL; #L4960, 
Promega, Madison, WI) according to the manufacturer 
instructions using 1 μg of RNA in each reaction at 70% 
v/v of RRL supplemented with 0.1 mM of an amino acid 
mixture minus leucine (#L9951, Promega), 0.1 mM of an 
amino acid mixture minus methionine (#L9961, Promega) 
and 40 U of RNAsin (#E00382, Thermo Scientific, 
ThermoFisher Scientific). The final volume in all reactions 
was 50 μL. As a negative control, a reaction without RNA 
was used. All the reactions were carried out during 90 
minutes at 30°C and after that, the reactions were stopped 
placing the tubes at -20°C.
Statistical analysis
Statistical significance for experiments in which 
data were compared to a standard or predetermined value 
(Pfaffl’s graphs), was performed by using a Wilcoxon 
test (for non-parametrical data) or a two-tailed t-test (for 
parametrical data). In experiments where data between 
several groups were compared, Mann-Whitney test (for 
non-parametrical data) or a paired or unpaired two-tailed 
t-test (for parametrical data) was performed. Data are 
presented as means ± standard error of the mean (s.e.m.) 
with sample size (n) indicating the number of samples 
(patients) or (n) indicating the number of independent 
experiments (cell lines). Significance of mean comparison 
was considered when p values were less than 0.05. All 
data were tested for normality with D’Agostino and 
Pearson omnibus test. The association between the 
protein expression of CXCR3, CXCR3A, CXCR3B and 
CXCL10 with each histopathological feature of PTC 
was determined by the calculation of the Odds Ratio 
(OR) by univariate analysis. The 95% of the confidence 
interval was also calculated for OR, resulting statistically 
important when did not cross the unit value. All analyses 
were performed using GraphPad Prism 5, version 5.01 ® 
software (GraphPad Prism, Inc). No statistical method 
was used to predetermine sample size therefore it was 
estimated according to biopsy availability.
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